文献速递复苏、休克与脓毒症心脑血管急症

成人院外心脏骤停:骨内通路与静脉通路的贝叶斯二次分析(PARAMEDIC-3试验)

Intraosseous versus intravenous access in adult out-of-hospital cardiac arrest: a Bayesian secondary analysis of the PARAMEDIC-3 randomised controlled trial.
PubMed 文献 · Resuscitation · 2026-09-25
一句话结论成人院外心脏骤停中,骨内优先策略较静脉优先策略更可能有害,30天生存改善概率仅18.4%。

这是PARAMEDIC-3随机对照试验的预先设定的贝叶斯二次分析,纳入6082例需建立血管通路的成人院外心脏骤停患者,比较骨内优先与静脉优先策略。使用无信息先验并校正关键基线特征后,骨内优先策略改善30天生存(OR>1.0)的后验概率为18.4%,劣于静脉优先(OR<1.0)的概率为81.6%,但中等效应(OR<0.75)的概率仅13.4%。自主循环恢复方面,骨内优先劣于静脉优先的概率达98.0%。结论认为骨内优先策略更可能有害而非有益,但整体效应可能不大。

要点

  • 成人院外心脏骤停需建立血管通路时,骨内优先策略改善30天生存的后验概率仅18.4%,不推荐常规首选骨内通路。
  • 骨内优先策略劣于静脉优先策略的后验概率:任何效应(OR<1.0)为81.6%,中等效应(OR<0.75)为13.4%。
  • 自主循环恢复(ROSC)方面,骨内优先劣于静脉优先的后验概率高达98.0%,床旁应优先尝试静脉通路。
  • 骨内优先产生中等或较大治疗效应的概率低,提示即使有害,整体效应也可能不大,无需绝对禁用。
  • 该分析为贝叶斯二次分析,使用无信息先验,结果需结合PARAMEDIC-3主要结果解读。

适用人群与场景

  • 成人院外心脏骤停且需要建立血管通路的患者(PARAMEDIC-3纳入标准)。
  • 排除人群及具体纳入/排除标准原文未提及。
  • 场景为院前急救,非急诊科或ICU内。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或目标值。
  • 策略比较为骨内优先与静脉优先建立血管通路,但具体操作流程原文未提及。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:PARAMEDIC-3随机对照试验的预先设定贝叶斯二次分析,样本量6082例,多中心(具体中心数原文未提及)。
  • 人群:成人院外心脏骤停需血管通路者;干预:骨内优先策略;对照:静脉优先策略。
  • 主要终点30天生存:骨内优先改善的后验概率18.4%(OR>1.0),劣于静脉优先的概率81.6%(OR<1.0)。
  • 骨内优先劣于静脉优先的概率:小效应(OR<0.9)为55.0%,中等效应(OR<0.75)为13.4%。
  • favorable神经功能结局:结果与30天生存相当(具体数值原文未提及)。
  • ROSC:骨内优先劣于静脉优先(OR<1.0)的后验概率98.0%。
  • 不良事件:原文未提及。

证据类型、等级与局限

  • 证据类型:随机对照试验的贝叶斯二次分析。
  • 证据等级或推荐强度:原文未提及。
  • 局限:使用无信息先验(代表最小先验知识);为二次分析;具体单中心/多中心、盲法等设计细节原文未提及。

对床旁实践的改变

  • 成人院外心脏骤停建立血管通路时,该分析支持静脉优先策略,不推荐常规骨内优先。
  • 骨内优先改善生存概率低(18.4%),且ROSC劣于静脉优先概率高(98.0%),床旁应优先尝试静脉通路。
  • 中等或大效应概率低(13.4%),提示整体效应可能不大,临床决策需结合具体情况。
  • 适用人群为成人院外心脏骤停需血管通路者;不适用人群及院内场景原文未提及。

指南或共识出处

  • PARAMEDIC-3随机对照试验(ISRCTN14223494)。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the clinical-effectiveness of an intraosseous-first strategy compared with an intravenous-first strategy in adult out-of-hospital cardiac arrest in a pre-planned Bayesian secondary analysis of the PARAMEDIC-3 trial.

METHODS: In PARAMEDIC-3, adults with out-of-hospital cardiac arrest requiring vascular access were randomised to either an intraosseous-first strategy or an intravenous-first strategy. In this analysis, we describe the probability that an intraosseous-first strategy was superior or inferior to an intravenous-first strategy, and the probability that this exceeds specific odds ratio thresholds. Our outcomes were 30-day survival (primary), favourable neurological outcome at hospital discharge and return of spontaneous circulation at hospital handover. Our primary analysis used non-informative priors, adjusted for key baseline characteristics.

RESULTS: In 6082 randomised participants, the posterior probability that an intraosseous-first strategy improved 30-day survival (odds ratio (OR) > 1.0) was 18.4%. The probability that an intraosseous-first strategy was inferior to an intravenous-first strategy was 81.6% for any effect (OR < 1.0), 55.0% for a small effect (OR < 0.9), and 13.4% for a moderate effect (OR < 0.75). For favourable neurological outcome, findings were comparable to 30-day survival. For return of spontaneous circulation, the posterior probability that an intraosseous-first strategy was inferior to an intravenous-first strategy (OR < 1.0) was 98.0%.

CONCLUSION: Based on non-informative priors, which represent minimal prior knowledge of the treatment effect, an intraosseous-first strategy in adult out-of-hospital cardiac arrest is more likely to be harmful, rather than beneficial. However, the low probability of a moderate or large treatment effect suggests that the overall treatment effect is likely to be modest.

TRIAL REGISTRATION: ISRCTN14223494.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Couper K, Ji C, Deakin CD, et al. Intraosseous versus intravenous access in adult out-of-hospital cardiac arrest: a Bayesian secondary analysis of the PARAMEDIC-3 randomised controlled trial. Resuscitation. 2026. PMID: 42790855. doi:10.1016/j.resuscitation.2026.111335

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。